Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NMCNN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD48A
|
|||||
| Synonyms |
SGNCD48A; SGN CD48A
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Humanized Anti-SLAMF2 SGN-CD48A mAb
|
Antibody Info | ||||
| Antigen Name |
CD48 antigen (CD48)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Beta-Glucuronidase cleavable linker
|
Linker Info | ||||
| Combination Type |
Glucuronide-MMAE
|
|||||
| TTD ID | ||||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
| Standard Type | NCT Number | Clinical Status | Clinical Trial Description |
|---|---|---|---|
| Undisclosed | NCT03379584 |
Phase 1
|
A phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma.
|
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Effective Concentration (EC50) |
1.00-11.00
|
ng/mL
|
Multiple myeloma cells
|
Multiple myeloma
|
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03379584 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma. | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 75.00% | Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | EJM cells | CVCL_2030 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 87.50% | Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | U-266 cells | CVCL_0015 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 100.00% | Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.00-11.00 ng/mL | High CD48 expresion (CD48+++/++; 1260 MSLN molecules/cell) | ||
| Method Description |
Cytotoxic activity of SGN-CD48A was demonstrated in a panel of human MM cell lines in vitro.
|
||||
| In Vitro Model | Multiple myeloma | Multiple myeloma cells | Homo sapiens | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.